Supernus Pharma (NASDAQ: SUPN) reported Q2 EPS of $0.57, $0.14 better than the analyst estimate of $0.43. Revenue for the quarter came in at $99.5 million versus the consensus estimate of $99.86 million.

• Total revenue of $99.5 million, a 31% increase over 2017
• Net product sales of $97.0 million, a 32% increase over 2017
• Operating earnings of $35.7 million, a 37% increase over 2017
• Diluted earnings per share (GAAP) of $0.57, a 78% increase over 2017
• Completed enrollment in the first SPN-812 Phase III trial (P301), with data expected in the fourth quarter of 2018

“Solid commercial execution has enabled Supernus to generate another strong quarter of growth, setting a new record for both Trokendi XR and Oxtellar XR quarterly net product sales,” said Jack Khattar, President and CEO of Supernus Pharmaceuticals.

GUIDANCE:

Supernus Pharma sees FY2017 revenue of $385-400 million, versus the consensus of $403.91 million.

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.